Miplyffa: Dosage Form, Projected Sales, NCE-1 Date | Arimoclomol

Miplyffa

Miplyffa is used to treat Niemann-Pick disease type C. The combination of the drug Miplyffa and miglustat is suggested for the treatment of neurological symptoms of Niemann-Pick disease type C in adults as well as children who are at least two years old.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Arimoclomol
Innovator :

ZEVRA DENMARK AS
Approval Date :

20-Sep-24
NCE-1 Date :

20-Sep-28
NCE Date :

20-Sep-29
Dosage Form :

Oral Capsules
Strength :

47mg, 62mg, 93mg and 124mg
Therapeutic Category :

Neuroprotective
Revenue ($M) :

10

Year-wise Projected Sales ($M) :

2025 :

77
2026 :

144
2027 :

191
2028 :

225
2029 :

248
2030 :

267
2031 :

285

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Miplyffa

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?